Content area

Abstract

Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, the B-cell receptor (BCR) and nuclear factor- κB (NF-κB) pathways are activated in the lymph node (LN) microenvironment. Thus, model systems mimicking tumor–host interactions are important tools to study CLL biology and pathogenesis. We investigated whether the recently established NOD/scid/γcnull (NSG) mouse xenograft model can recapitulate the effects of the human microenvironment. We assessed, therefore, tumor characteristics previously defined in LN-resident CLL cells, including proliferation, and activation of the BCR and NF-κB pathways. We found that the murine spleen (SP) microenvironment supported CLL cell proliferation and activation to a similar degree than the human LN, including induction of BCR and NF-κB signaling in the xenografted cells. Next, we used this model to study ibrutinib, a Bruton’s tyrosine kinase inhibitor in clinical development. Ibrutinib inhibited BCR and NF-κB signaling induced by the microenvironment, decreased proliferation, induced apoptosis and reduced the tumor burden in vivo. Thus, our data demonstrate that the SP of xenografted NSG mice can, in part, recapitulate the role of the human LN for CLL cells. In addition, we show that ibrutinib effectively disrupts tumor–host interactions essential for CLL cell proliferation and survival in vivo.

Details

Title
Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
Author
Herman S E M 1 ; Sun, X 1 ; McAuley, E M 1 ; Hsieh, M M 1 ; Pittaluga, S 2 ; Raffeld, M 2 ; Liu, D 1 ; Keyvanfar, K 1 ; Chapman, C M 1 ; Chen, J 1 ; Buggy, J J 3 ; Aue, G 1 ; Tisdale, J F 1 ; Pérez-Galán, P 4 ; Wiestner, A 1 

 Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, USA (GRID:grid.279885.9) (ISNI:0000 0001 2293 4638) 
 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 Pharmacyclics Inc., Sunnyvale, USA (GRID:grid.430227.0) 
 Institut d’Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Department of Hemato-Oncology, Barcelona, Spain (GRID:grid.10403.36) 
Pages
2311-2321
Publication year
2013
Publication date
Dec 2013
Publisher
Nature Publishing Group
ISSN
08876924
e-ISSN
14765551
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2645728343
Copyright
© Macmillan Publishers Limited 2013.